Solve FSHD
VC Fund
Vancouver, Canada
Solve FSHD is a VC fund in Vancouver focused on Biotechnology and Therapeutics. Solve FSHD fosters innovation and accelerates critical research toward a treatment for facioscapulohumeral muscular dystrophy.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 88%
Last updated:
For AI agents: llms.txt
Industries Solve FSHD invests in
Stages Solve FSHD invests in
Countries Solve FSHD invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dennis J. "Chip" Wilson
|
|||
Investment Focus
Industry
- Biotechnology 6 (75%)
- Therapeutics 3 (38%)
- Health Care 2 (25%)
- Life Science 2 (25%)
- Medical 1 (13%)
Stage
- Seed 2 (25%)
- Grant 2 (25%)
- Series B 2 (25%)
- Post-IPO Equity 1 (13%)
Country
- United States 6 (75%)
- Japan 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Dennis J. "Chip" Wilson
Founder
|
Founder | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Restem Group
|
Restem Group is a leading clinical-stage biopharmaceutical company focused on the discovery and development of patients. | Grant / Dec 08, 2025 | |
Modalis Therapeutics
|
Modalis Therapeutics Corporation is an biotech company focusing on developing transformative therapeutics for unmet medical needs using its proprietary technologies on CRISPR and protein engineering platforms. The company has a strong foundation on intellectual property licensed from the University of Tokyo. | Post-IPO Equity / Jun 09, 2025 | |
Epicrispr Biotechnologies
|
The Gene Expression Modulation System (GEMS) technology from Epic-Bio combines a DNA-binding protein, a tailored guide RNA, and any of a wide range of modulator proteins to generate a powerful new type of genetic medicine. GEMS medicines have the ability to precisely modify gene expression both in and out of the body. They are mutation-independent,which means that a single GEMS design can address the majority or all genetic subtypes of a disease. | $68M / Series B / Mar 26, 2025 | |
Vita Therapeutics
|
Vita Therapeutics is a cell engineering company that develops life-transformative treatments. Vita utilizes induced pluripotent stem cell technology to engineer specific cell types designed to replace those that are defective in patients. | $31M / Series B / Oct 12, 2022 | |
|
Vita Therapeutics
|
Vita Therapeutics is a cell engineering company that develops life-transformative treatments. Vita utilizes induced pluripotent stem cell technology to engineer specific cell types designed to replace those that are defective in patients. | $31M / Series B / Oct 12, 2022 | |
Altay Therapeutics
|
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for chronic inflammatory conditions. It is currently focused on finding curative therapies for fibrosis, NASH, and liver cancer. It develops novel small molecule drugs against transcriptional regulators that are validated drivers of disease. It wasfounded in 2019 and is headquartered in San Francisco, California. | $3M / Seed / Sep 21, 2022 | |
n-Lorem Foundation
|
N-Lorem Foundation uses antisense technology to create individualized treatments for patients with nano-rare diseases. Antisense medicines, also known as antisense oligonucleotides or ASOs, are intended to precisely connect with RNA, preventing the process of generating a protein that causes sickness. This disrupts the course of diseases, from themost uncommon to those that affect millions of people. For nano-rare patients who are amenable to the company's technology, the n-Lorem Foundation provides the infrastructure, resources, and access necessary for them to receive experimental Antisense oligonucleotides (ASOs) without charge. | $1M / Grant / Sep 13, 2022 | |
Armatus Bio
|
Armatus Bio is a new precision pharmaceutical firm based on genetic science and bioengineering. Precision therapeutics are being developed with dynamic thinking and rigorous processes to deliver life-saving drugs more effectively and efficiently than ever before. They believe that engineering will be a major catalyst in moving precision treatmentsfrom research and development to mainstream care. To stimulate disruptive therapeutic innovation, they are using advanced engineering methodologies to create synergistic technologies. | $3M / Seed |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Solve FSHD invest in?
Solve FSHD invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Seed and Grant stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Solve FSHD?
Public channels for Solve FSHD include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Solve FSHD?
The team at Solve FSHD includes Dennis J. "Chip" Wilson (Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
